Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Review, H1 2016

  • ID: 3788887
  • Report
  • 72 pages
  • Global Markets Direct
1 of 6
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Review, H1 2016

Summary

‘Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein)
- The report reviews Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics and enlists all their major and minor projects
- The report assesses Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Overview

Therapeutics Development

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Products under Development by Stage of Development

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Products under Development by Therapy Area

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Products under Development by Indication

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Products under Development by Companies

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Companies Involved in Therapeutics Development

Alteogen Inc.

Chengdu Kanghong Pharmaceuticals Group Co., Ltd.

Clearside BioMedical, Inc.

Formycon AG

Regeneron Pharmaceuticals, Inc.

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Drug Profiles

(aflibercept + nesvacumab) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(aflibercept + rinucumab) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(aflibercept + triamcinolone acetonide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

conbercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-186 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THR-317 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ziv-aflibercept (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Dormant Projects

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Discontinued Products

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Featured News & Press Releases

Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists’ guidance

May 02, 2016: Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma

Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion

Mar 15, 2016: BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403

Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven

Feb 29, 2016: Formycon discloses details on second pipeline product - FYB203 is a biosimilar for Eylea (aflibercept)

Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403

Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration

Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization

Sep 25, 2015: Bayer’s Eye Drug Recommended for EU Approval in Fifth Indication

Sep 18, 2015: Three-Year Results with EYLEA Show Sustained Improvement in Vision for People with Diabetic Macular Edema

Jul 21, 2015: NICE gives green light to aflibercept solution for treating serious eye condition

Jun 26, 2015: Bayer Receives Approval for EYLEA for the Treatment of Retinal Vein Occlusion in Japan

Jun 02, 2015: NICE Recommended Aflibercept Solution For Injection For Treating Serious Diabetic Eye Condition In Final Draft Guidance

May 06, 2015: Data presented at ARVO 2015 further showcase the real-world efficacy of EYLEA in UK clinical practice

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 72List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Alteogen Inc., H1 2016

Pipeline by Chengdu Kanghong Pharmaceuticals Group Co., Ltd., H1 2016

Pipeline by Clearside BioMedical, Inc., H1 2016

Pipeline by Formycon AG, H1 2016

Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 58List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies.The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5, 1 and 4 respectively.

Our latest report Placental Growth Factor – Pipeline Review, H1 2016, outlays comprehensive information on the Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Alteogen Inc.
Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Clearside BioMedical, Inc.
Formycon AG
Regeneron Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll